98 related articles for article (PubMed ID: 26652977)
1. dfcomb: An R-package for phase I/II trials of drug combinations.
Riviere MK; Jourdan JH; Zohar S
Comput Methods Programs Biomed; 2016 Mar; 125():117-33. PubMed ID: 26652977
[TBL] [Abstract][Full Text] [Related]
2. Application of Bayesian hierarchical models for phase I/II clinical trials in oncology.
Yada S; Hamada C
Pharm Stat; 2017 Mar; 16(2):114-121. PubMed ID: 27892650
[TBL] [Abstract][Full Text] [Related]
3. Beyond the 3+3 method: expanded algorithms for dose- escalation in Phase I oncology trials of two agents.
Braun TM; Alonzo TA
Clin Trials; 2011 Jun; 8(3):247-59. PubMed ID: 21730075
[TBL] [Abstract][Full Text] [Related]
4. Adaptive phase I/II clinical trials for drug combination assessment in oncology using the outcomes of each cycle.
Yada S; Hamada C
Pharm Stat; 2017 Nov; 16(6):433-444. PubMed ID: 28840635
[TBL] [Abstract][Full Text] [Related]
5. Practical designs for Phase I combination studies in oncology.
Wages NA; Ivanova A; Marchenko O
J Biopharm Stat; 2016; 26(1):150-66. PubMed ID: 26379085
[TBL] [Abstract][Full Text] [Related]
6. pocrm: an R-package for phase I trials of combinations of agents.
Wages NA; Varhegyi N
Comput Methods Programs Biomed; 2013 Oct; 112(1):211-8. PubMed ID: 23871691
[TBL] [Abstract][Full Text] [Related]
7. Designs of drug-combination phase I trials in oncology: a systematic review of the literature.
Riviere MK; Le Tourneau C; Paoletti X; Dubois F; Zohar S
Ann Oncol; 2015 Apr; 26(4):669-674. PubMed ID: 25403591
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II adaptive design for drug combination oncology trials.
Wages NA; Conaway MR
Stat Med; 2014 May; 33(12):1990-2003. PubMed ID: 24470329
[TBL] [Abstract][Full Text] [Related]
9. A parallel phase I/II clinical trial design for combination therapies.
Huang X; Biswas S; Oki Y; Issa JP; Berry DA
Biometrics; 2007 Jun; 63(2):429-36. PubMed ID: 17688495
[TBL] [Abstract][Full Text] [Related]
10. A Dose-Finding Method Based on Multiple Dosing in Two-Agent Combination Phase I Trials.
Kakurai Y; Hirakawa A; Hamada C
J Biopharm Stat; 2015; 25(5):1065-76. PubMed ID: 25369852
[TBL] [Abstract][Full Text] [Related]
11. On the coherence of model-based dose-finding designs for drug combination trials.
Park Y; Liu S
PLoS One; 2020; 15(11):e0242561. PubMed ID: 33253260
[TBL] [Abstract][Full Text] [Related]
12. Clinical trial design in metastatic breast cancer: a commentary.
Levine M
Can J Oncol; 1995 Dec; 5 Suppl 1():40-2. PubMed ID: 8853523
[TBL] [Abstract][Full Text] [Related]
13. Adaptive designs for dual-agent phase I dose-escalation studies.
Harrington JA; Wheeler GM; Sweeting MJ; Mander AP; Jodrell DI
Nat Rev Clin Oncol; 2013 May; 10(5):277-88. PubMed ID: 23507740
[TBL] [Abstract][Full Text] [Related]
14. Dose-escalation models for combination phase I trials in oncology.
Hamberg P; Ratain MJ; Lesaffre E; Verweij J
Eur J Cancer; 2010 Nov; 46(16):2870-8. PubMed ID: 20691584
[TBL] [Abstract][Full Text] [Related]
15. A Bayesian hierarchal modeling approach to shortening phase I/II trials of anticancer drug combinations.
Yada S; Hamada C
Pharm Stat; 2018 Nov; 17(6):750-760. PubMed ID: 30112847
[TBL] [Abstract][Full Text] [Related]
16. Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations.
Thall PF; Cook JD; Estey EH
J Biopharm Stat; 2006; 16(5):623-38. PubMed ID: 17037262
[TBL] [Abstract][Full Text] [Related]
17. Designs for single- or multiple-agent phase I trials.
Conaway MR; Dunbar S; Peddada SD
Biometrics; 2004 Sep; 60(3):661-9. PubMed ID: 15339288
[TBL] [Abstract][Full Text] [Related]
18. Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios.
Yin G; Li Y; Ji Y
Biometrics; 2006 Sep; 62(3):777-84. PubMed ID: 16984320
[TBL] [Abstract][Full Text] [Related]
19. Recent developments in adaptive designs for Phase I/II dose-finding studies.
Zohar S; Chevret S
J Biopharm Stat; 2007; 17(6):1071-83. PubMed ID: 18027217
[TBL] [Abstract][Full Text] [Related]
20. [Combination phase I trials].
Masuda N
Gan To Kagaku Ryoho; 1996 Jan; 23(2):219-25. PubMed ID: 8611050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
